ZA201808102B - Methods for treating heterotopic ossification - Google Patents

Methods for treating heterotopic ossification

Info

Publication number
ZA201808102B
ZA201808102B ZA2018/08102A ZA201808102A ZA201808102B ZA 201808102 B ZA201808102 B ZA 201808102B ZA 2018/08102 A ZA2018/08102 A ZA 2018/08102A ZA 201808102 A ZA201808102 A ZA 201808102A ZA 201808102 B ZA201808102 B ZA 201808102B
Authority
ZA
South Africa
Prior art keywords
methods
heterotopic ossification
reduce
flare
ups
Prior art date
Application number
ZA2018/08102A
Other languages
English (en)
Inventor
Desjardins Clarissa
Roy Grogan Donna
Neal Packman Jeffrey
Harnett Mark
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of ZA201808102B publication Critical patent/ZA201808102B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2018/08102A 2016-06-08 2018-11-29 Methods for treating heterotopic ossification ZA201808102B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08
PCT/CA2017/050701 WO2017210792A1 (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Publications (1)

Publication Number Publication Date
ZA201808102B true ZA201808102B (en) 2024-04-24

Family

ID=60578331

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/08102A ZA201808102B (en) 2016-06-08 2018-11-29 Methods for treating heterotopic ossification

Country Status (18)

Country Link
US (6) US10864194B2 (enExample)
EP (2) EP3468554B1 (enExample)
JP (2) JP7023868B2 (enExample)
KR (1) KR102486607B1 (enExample)
CN (2) CN109562099A (enExample)
AU (2) AU2017276835B2 (enExample)
BR (1) BR112018075422A2 (enExample)
CA (1) CA3025854A1 (enExample)
CL (1) CL2018003502A1 (enExample)
EA (1) EA201892497A1 (enExample)
ES (1) ES2963348T3 (enExample)
IL (3) IL263440B (enExample)
MX (2) MX390115B (enExample)
MY (1) MY200642A (enExample)
PH (1) PH12018502563A1 (enExample)
SG (1) SG11201810658PA (enExample)
WO (1) WO2017210792A1 (enExample)
ZA (1) ZA201808102B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
ES2963348T3 (es) * 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
EP4186505A4 (en) * 2020-06-11 2024-06-19 Yang Sheng Tang Company, Ltd. USE OF PALOVAROTEN TO TREAT HBV VIRUS
EP4470537A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
EP4470536A1 (en) * 2023-05-30 2024-12-04 Queen's University At Kingston Compound for use in treating fibrodysplasia ossificans progressiva (fop)
CN119185298B (zh) * 2024-10-30 2025-09-26 武汉大学人民医院（湖北省人民医院） 帕罗伐汀在制备用于治疗脑出血后急性脑损伤的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
WO2002028810A2 (en) 2000-10-02 2002-04-11 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
BR0212583A (pt) 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
AU2002340886B2 (en) 2001-09-18 2008-01-31 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists II
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US20060210638A1 (en) 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
US20090281184A1 (en) 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
US20070213308A1 (en) * 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
CA2647275A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
EP2379174A4 (en) 2008-12-18 2012-11-14 Astrazeneca Ab PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
US20120277156A1 (en) * 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US20120077786A1 (en) 2010-09-27 2012-03-29 Byron David A Methods and compositions for disease treatment using inhalation
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
AU2013222345B2 (en) * 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US10702502B2 (en) 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
EP3201187A4 (en) * 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
WO2020118405A1 (en) 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
JP2019517528A (ja) 2019-06-24
NZ748939A (en) 2025-03-28
CN120204216A (zh) 2025-06-27
US11622959B2 (en) 2023-04-11
CA3025854A1 (en) 2017-12-14
AU2017276835A1 (en) 2018-12-13
JP2022019995A (ja) 2022-01-27
EP3468554A1 (en) 2019-04-17
US20210069152A1 (en) 2021-03-11
IL317726A (en) 2025-02-01
EP4249490A2 (en) 2023-09-27
BR112018075422A2 (pt) 2019-03-12
MX390115B (es) 2025-03-20
CL2018003502A1 (es) 2019-04-26
EP3468554B1 (en) 2023-08-09
MY200642A (en) 2024-01-08
CN109562099A (zh) 2019-04-02
US20260021073A1 (en) 2026-01-22
SG11201810658PA (en) 2018-12-28
WO2017210792A1 (en) 2017-12-14
IL295440A (en) 2022-10-01
EA201892497A1 (ru) 2019-05-31
EP3468554C0 (en) 2023-08-09
US20190216781A1 (en) 2019-07-18
US20240350457A1 (en) 2024-10-24
IL295440B2 (en) 2025-05-01
US12458626B2 (en) 2025-11-04
ES2963348T3 (es) 2024-03-26
IL263440A (en) 2019-01-31
PH12018502563A1 (en) 2019-10-14
US10864194B2 (en) 2020-12-15
KR102486607B1 (ko) 2023-01-11
US20230285360A1 (en) 2023-09-14
MX2018015108A (es) 2019-08-29
IL295440B1 (en) 2025-01-01
MX2022001991A (es) 2022-03-11
AU2017276835B2 (en) 2022-03-31
US20240277667A1 (en) 2024-08-22
AU2022202148A1 (en) 2022-04-21
EP3468554A4 (en) 2020-01-22
IL263440B (en) 2022-09-01
KR20190017883A (ko) 2019-02-20
US12138245B2 (en) 2024-11-12
JP7023868B2 (ja) 2022-02-22
EP4249490A3 (en) 2023-12-13
AU2022202148B2 (en) 2023-08-24
US12201614B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
PH12018502563A1 (en) Methods for treating heterotopic ossification
CL2020001852A1 (es) Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
NZ737399A (en) Ccr2 modulators
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
GB2541571A (en) Pharmaceutical compositions
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2018006582A (es) Conjugados de farmaco de anticuerpo her2 especificos de sitio.
DK3484502T3 (da) Blodplasmafraktioner til behandling mod aldersrelaterede kognitive forstyrrelser
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12017500732B1 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
SMT202300325T1 (it) Composizioni farmaceutiche antitumorali per terapia combinata
MX2019006551A (es) Terapia génica para mucopolisacaridosis de tipo ii.
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.